Targeted Genetics Initiates Phase I Trial for Childhood Blindness
Posted on: Thursday, 3 May 2007, 06:00 CDT
US biotech firm Targeted Genetics has announced the start of clinical trials in the UK into a gene therapy treatment for a form of childhood blindness.
University College London's Institute of Ophthalmology and Moorfields Eye Hospital, with funding from the UK Department of Health, are trialing the treatment in adults and children with a progressive deterioration in vision caused by an abnormality in the RPE65 gene.
In affected individuals, this defect prevents normal function of the retina, the light-sensitive layer of cells at the back of the eye. The therapy involves an adeno-associated virus vector manufactured by Targeted Genetics to deliver a normal copy of the RPE65 gene into the cells of the retina to help them to function normally.
Professor Robin Ali, who is leading the investigation, said: "We have been developing gene-based treatments for eye disease for almost 15 years but until now we have been evaluating the technology only in the laboratory.
"Testing it for the first time in patients is very important and exciting and represents a significant step towards establishing gene therapy for the treatment of many different eye conditions."
Source: Datamonitor
Related Articles
- AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease With AMT's Proprietary Gene Therapy Platform
- Ability of Neurologix's Gene Transfer Therapy to Quiet Abnormal Brain Activity in Parkinson's Disease Patients Reported in PNAS
- RheoGene, Inc. Merger With Intrexon Corporation Creates Biotech Firm Targeting Gene-Based Therapies
- The Cancer Cure Coalition Supports the Nomination of Dr. Andrew Von Eschenbach As Commissioner of the U.S. FDA and Calls for the Approval of Advexin, a New Gene Therapy Treatment for Cancer
- Cancer Patient Receives First Proton Therapy Treatment at University of Florida Proton Therapy Institute
- Gene Therapy Treatments Face Long Road Ahead
- Neurologix Pre-Clinical Results Show Potential for Gene Therapy Treatment of Huntington's Disease
- New gene silencing therapy for cervical cancer
- Inovio Study Results of Gene-Based Therapies for HIV and Vascular Disease Published in Scientific Journals; Articles Published in Collaboration With Boehringer Ingelheim and Chiron Corporation
- Prostate Cancer and the Principles of Hormone Therapy Treatment
 |
 |
User Comments (0)
RSS Feeds